Skip to main content
Premium Trial:

Request an Annual Quote

Syngenta, Chromatin Extend Gene Stacking Technology Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chromatin today announced an extension of its agreement with Syngenta Biotechology for use of Chromatin's gene stacking technology for soybean applications.

The deal builds on earlier agreements between the two firms. The original deal, forged in 2007, gave Syngenta non-exclusive rights to use Chromatin's technology for trait genes in corn and soybean. Two years later, Syngenta acquired exclusive worldwide research and commercial license rights to the technology for use in sugar cane.

The two firms today said that they have begun work to further the gene stacking technology for use on soybeans. They did not elaborate.

Terms of the extension were not disclosed.

Chromatin is based in Chicago and develops technologies for use in the agricultural, energy, chemical, nutritional, and pharmaceutical areas. Its gene stacking technology uses a plant's own DNA to deliver genes on a mini-chromosome, genetic elements built to deliver multiple traits "and accelerate the development of new products, providing new benefits to growers, industrial bioprocessors, and consumers," Chromatin said in a statement.

Syngenta is an agribusiness based in Basel, Switzerland, engaged in the development, manufacture, and marketing of products for the enhancement of crop yields and food quality.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more